Related Experiment Video

Updated: Jun 25, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Targeting EGFR resistance networks in head and neck cancer

Vladimir Ratushny1, Igor Astsaturov, Barbara A Burtness

  • 1Program in Head and Neck Cancer, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, USA.

Cellular Signalling
|March 5, 2009
PubMed

Insights

Targeted cancer therapies, like those targeting the Epidermal Growth Factor Receptor (EGFR), show complex patient responses. Personalized treatment strategies are evolving to account for tumor-specific factors influencing therapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Oncoproteins are frequently overexpressed or activated in various cancers, making them key targets for novel therapeutics.
  • Epidermal Growth Factor Receptor (EGFR)-targeted therapies, including small molecules and antibodies, have been clinically used for over a decade.
  • Patient responses to EGFR-targeted drugs exhibit complexity influenced by multiple biological and environmental factors.

Purpose of the Study:

  • To review the complexities of patient response to EGFR-targeted therapies.
  • To examine how tumor-specific signaling environments and external factors modulate treatment outcomes.
  • To highlight squamous cell carcinoma of the head and neck (SCCHN) as a model for understanding EGFR-involved cancer treatment.

Main Methods:

  • Literature review of clinical outcomes and biological factors influencing EGFR-targeted drug response.
  • Analysis of genetic, epigenetic, and environmental modulators of treatment efficacy.
  • Comparative examination of SCCHN with other cancer types regarding EGFR signaling and therapeutic strategies.

Main Results:

  • Patient response to EGFR-targeted drugs is modulated by tumor progenitor cell lineage, co-mutations, epigenetic changes, and environmental factors like inflammation and viral infections.
  • Second and third-generation therapies are increasingly personalized, incorporating knowledge of cancer-specific signaling pathways.
  • SCCHN presents unique biological characteristics that impact the design of EGFR-targeted treatment modalities.

Conclusions:

  • Understanding the intricate factors influencing EGFR-targeted therapy response is crucial for optimizing treatment.
  • Personalized medicine approaches, tailored to individual tumor biology and environment, represent the future of cancer therapeutics.
  • EGFR-targeted drug development and application require consideration of cancer-specific contexts, exemplified by SCCHN.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...